Endothelial functions of sphingosine-1-phosphate

Cellular Physiology and Biochemistry

Volumn 26, Issue 1, 2010, Pages 87-96

  Lucke, Susann ^a   Levkau, Bodo ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Arterial tone; FTY720; Inflammation; Leak; Permeability; Sphingosine kinases; Sphingosine 1 phosphate (S1P)

Indexed keywords

CYCLOOXYGENASE 2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR; FINGOLIMOD; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VERY LOW DENSITY LIPOPROTEIN;

ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; CLINICAL TRIAL; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; KIDNEY GRAFT REJECTION; LEUKOCYTE ADHERENCE; LYMPHOCYTOPENIA; MORPHOGENESIS; MULTIPLE SCLEROSIS; NEGATIVE FEEDBACK; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TISSUE PERFUSION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 77952946424     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315109     Document Type: Review

References (102)

1. Spiegel S, Milstien S: Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003;4:397-407.
2. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG, Coughlin SR: Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316:295-298.
3. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C, Hla T: Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res 2008;102:669-676.
4. Hannun YA, Obeid LM: Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9:139-150.
5. van Meer G, Voelker DR, Feigenson GW: Membrane lipids: Where they are and how they behave. Nat Rev Mol Cell Biol 2008;9:112-124.
6. Kobayashi N, Nishi T, Hirata T, Kihara A, Sano T, Igarashi Y, Yamaguchi A: Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner. J Lipid Res 2006;47:614-621.
7. Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S: Role of abcc1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 2006;103:16394-16399.
8. Lee YM, Venkataraman K, Hwang SI, Han DK, Hla T: A novel method to quantify sphingosine 1-phosphate by immobilized metal affinity chroma-tography (imac). Prostaglandins Other Lipid Mediat 2007;84:154-162.
9. Kawahara A, Nishi T, Hisano Y, Fukui H, Yamaguchi A, Mochizuki N: The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. Science 2009;323:524-527.
10. Osborne N, Brand-Arzamendi K, Ober EA, Jin SW, Verkade H, Holtzman NG, Yelon D, Stainier DY: The spinster homolog, two of hearts, is required for sphingosine 1-phosphate signaling in zebrafish. Curr Biol 2008;18:1882-1888.
11. Kupperman E, An S, Osborne N, Waldron S, Stainier DY: A sphingosine-1-phosphate receptor regulates cell migration during vertebrate heart development. Nature 2000;406:192-195.
12. Okajima F: Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: Is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta 2002;1582:132-137.
13. Zhang B, Tomura H, Kuwabara A, Kimura T, Miura S, Noda K, Okajima F, Saku K: Correlation of high density lipoprotein (hdl)-associated sphingosine 1-phosphate with serum levels of hdl-cholesterol and apolipoproteins. Atherosclerosis 2005;178:199-205.
14. Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, Ui M, Okajima F: Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 2000;352 Pt 3:809-815.
15. Kontush A, Therond P, Zerrad A, Couturier M, Negre-Salvayre A, de Souza JA, Chantepie S, Chapman MJ: Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense hdl3 particles: Relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007;27:1843-1849.
16. Bandhuvula P, Li Z, Bittman R, Saba JD: Sphingosine 1-phosphate lyase enzyme assay using a bodipy-labeled substrate. Biochem Biophys Res Commun 2009;380:366-370.
17. Rivera R, Chun J: Biological effects of lysophospholipids. Rev Physiol Biochem Pharmacol 2008;160:25-46.
18. Olivera A, Spiegel S: Sphingosine-1-phosphate as second messenger in cell proliferation induced by pdgf and fcs mitogens. Nature 1993;365:557-560.
19. Hobson JP, Rosenfeldt HM, Barak LS, Olivera A, Poulton S, Caron MG, Milstien S, Spiegel S: Role of the sphingosine-1-phosphate receptor edg-1 in pdgf-induced cell motility. Science 2001;291:1800-1803.
20. Waters C, Sambi B, Kong KC, Thompson D, Pitson SM, Pyne S, Pyne NJ: Sphingosine 1-phosphate and platelet-derived growth factor (pdgf) act via pdgf beta receptor-sphingosine 1-phosphate receptor complexes in airway smooth muscle cells. J Biol Chem 2003;278:6282-6290.
21. Tanimoto T, Jin ZG, Berk BC: Transactivation of vascular endothelial growth factor (vegf) receptor flk-1/kdr is involved in sphingosine 1-phosphate-stimulated phosphorylation of akt and endothelial nitric-oxide synthase (enos). J Biol Chem 2002;277:42997-43001.
22. Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, Urbich C, Spyridopoulos I, Chun J, Brinkmann V, Keul P, Levkau B, Zeiher AM, Dimmeler S, Haendeler J: Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the cxcr4-dependent signaling pathway via the s1p3 receptor. Arterioscler Thromb Vasc Biol 2007;27:275-282.
23. Ryser MF, Ugarte F, Lehmann R, Bornhauser M, Brenner S: S1p(1) overexpression stimulates s1p-dependent chemotaxis of human cd34+ hemato-poietic progenitor cells but strongly inhibits sdf-1/cxcr4-dependent migration and in vivo homing. Mol Immunol 2008;46:166-171.
24. Kimura T, Boehmler AM, Seitz G, Kuci S, Wiesner T, Brinkmann V, Kanz L, Mohle R: The sphingosine 1-phosphate receptor agonist fty720 supports cxcr4-dependent migration and bone marrow homing of human cd34+ progenitor cells. Blood 2004;103:4478-4486.
25. Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Radeke H, Schafer-Korting M, Pfeilschifter J, Huwiler A: Sphingosine 1-phosphate cross-activates the smad signaling cascade and mimics transforming growth factor-beta-induced cell responses. J Biol Chem 2004;279:35255-35262.
26. Rosen H, Gonzalez-Cabrera P, Marsolais D, Cahalan S, Don AS, Sanna MG: Modulating tone: The overture of s1p receptor immunotherapeutics. Immunol Rev 2008;223:221-235.
27. Schwab SR, Cyster JG: Finding a way out: Lymphocyte egress from lymphoid organs. Nat Immunol 2007;8:1295-1301.
28. Rosen H, Sanna G, Alfonso C: Egress: A receptor-regulated step in lymphocyte trafficking. Immunol Rev 2003;195:160-177.
29. Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, Derian CK, Andrade-Gordon P, Rosen H, Ruf W: Dendritic cell par1-s1p3 signalling couples coagulation and inflammation. Nature 2008;452:654-658.
30. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP, Wei SH, Parker I, Jo E, Cheng WC, Cahalan MD, Wong CH, Rosen H: Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral s1p1 antagonist in vivo. Nat Chem Biol 2006;2:434-441.
31. Lynch KR, Macdonald TL: Sphingosine 1-phosphate chemical biology. Biochim Biophys Acta 2008;1781:508-512.
32. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S: Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009;78:743-768.
33. Massberg S, von Andrian UH: Fingolimod and sphingosine-1-phosphate- modifiers of lymphocyte migration. N Engl J Med 2006;355:1088-1091.
34. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-349.
35. Parini P, Johansson L, Broijersen A, Angelin B, Rudling M: Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest 2006;36:98-104.
36. Sloop CH, Dory L, Roheim PS: Interstitial fluid lipoproteins. J Lipid Res 1987;28:225-237.
37. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR: Intestinal abca1 directly contributes to hdl biogenesis in vivo. J Clin Invest 2006;116:1052-1062.
38. Pfalzer B, Hamm H, Beisiegel U, Ostendorf P: Lipoproteins and apolipo-proteins in human pleural effusions. J Lab Clin Med 1992;120:483-493.
39. Sattler K, Levkau B: Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009;82:201-211.
40. Shaul PW, Mineo C: Hdl action on the vascular wall: Is the answer no? J Clin Invest 2004;113:509-513.
41. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW: High-density lipoprotein binding to scavenger receptor-bi activates endothelial nitric oxide synthase. Nat Med 2001;7:853-857.
42. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B: Hdl induces no-dependent vasorelaxation via the lysophospholipid receptor s1p3. J Clin Invest 2004;113:569-581.
43. Tolle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S, Keul P, Assmann G, Chun J, Levkau B, van der Giet M, Nofer JR: Hdl-associated lysosphingolipids inhibit nad(p)h oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008;28:1542-1548.
44. Alewijnse AE, Peters SL: Sphingolipid signalling in the cardiovascular system: Good, bad or both? Eur J Pharmacol 2008;585:292-302.
45. Hla T: Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 2004;15:513-520.
46. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ: Lysophospholipids-receptor revelations. Science 2001;294:1875-1878.
47. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, Volpi M, Sha'afi RI, Hla T: Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999;99:301-312.
48. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S, Proia RL: Edg-1, the g protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000;106:951-961.
49. Ryu Y, Takuwa N, Sugimoto N, Sakurada S, Usui S, Okamoto H, Matsui O, Takuwa Y: Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular rac activity and cell migration in vascular smooth muscle cells. Circ Res 2002;90:325-332.
50. Allende ML, Proia RL: Sphingosine-1-phosphate receptors and the development of the vascular system. Biochim Biophys Acta 2002;1582:222-227.
51. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL: Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005;25:11113-11121.
52. Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu YP, Yamashita T, Proia RL: The sphingosine-1-phosphate receptors s1p1, s1p2, and s1p3 function coordinately during embryonic angioge-nesis. J Biol Chem 2004;279:29367-29373.
53. Skoura A, Sanchez T, Claffey K, Mandala SM, Proia RL, Hla T: Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest 2007;117:2506-2516.
54. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, Kundra V, Mills GB, Sabbadini RA: Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006;9:225-238.
55. Xie B, Shen J, Dong A, Rashid A, Stoller G, Campochiaro PA: Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J Cell Physiol 2009;218:192-198.
56. Dantas A P, Igarashi J, Michel T: Sphingosine 1-phosphate and control of vascular tone. Am J Physiol Heart Circ Physiol 2003;284:H2045-2052.
57. Salomone S, Potts EM, Tyndall S, Ip PC, Chun J, Brinkmann V, Waeber C: Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. Br J Pharmacol 2008;153:140-147.
58. Igarashi J, Michel T: Sphingosine-1-phosphate and modulation of vascular tone. Cardiovasc Res 2009;82:212-220.
59. Bolz SS, Vogel L, Sollinger D, Derwand R, Boer C, Pitson SM, Spiegel S, Pohl U: Sphingosine kinase modulates microva-scular tone and myogenic responses through activation of rhoa/rho kinase. Circulation 2003;108:342-347.
60. Peter BF, Lidington D, Harada A, Bolz HJ, Vogel L, Heximer S, Spiegel S, Pohl U, Bolz SS: Role of sphingosine-1-phosphate phosphohydrolase 1 in the regulation of resistance artery tone. Circ Res 2008;103:315-324.
61. Levkau B: Sphingosine-1-phosphate in the regulation of vascular tone: A finely tuned integration system of s1p sources, receptors, and vascular responsiveness. Circ Res 2008;103:231-233.
62. Lee JF, Zeng Q, Ozaki H, Wang L, Hand AR, Hla T, Wang E, Lee MJ: Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemo-taxis and barrier integrity. J Biol Chem 2006;281:29190-29200.
63. Mehta D, Konstantoulaki M, Ahmmed GU, Malik AB: Sphingosine 1-phosphate-induced mobilization of intracellular ca2+ mediates rac activation and adherens junction assembly in endothelial cells. J Biol Chem 2005;280:17320-17328.
64. Igarashi J, Michel T: Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase beta. Evidence for divergence and convergence of receptor-regulated endo-thelial nitric-oxide synthase signaling pathways. J Biol Chem 2001;276:36281-36288.
65. Takuwa Y, Okamoto Y, Yoshioka K, Takuwa N: Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta 2008;1781:483-488.
66. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW: Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of hdl. J Clin Invest 2007;117:746-756.
67. Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T: Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (s1p2r) and its downstream effectors rock and pten. Arterioscler Thromb Vasc Biol 2007;27:1312-1318.
68. Gon Y, Wood MR, Kiosses WB, Jo E, Sanna MG, Chun J, Rosen H: Retraction for "S1p3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by tnf". Proc Natl Acad Sci USA 2009;106:12561.
69. Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, Pham TH, Wong JS, Pappu R, Coughlin SR: Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest 2009;119:1871-1879.
70. Li X, Stankovic M, Bonder CS, Hahn CN, Parsons M, Pitson SM, Xia P, Proia RL, Vadas MA, Gamble JR: Basal and angiopoietin-1-mediated endothelial permeability is regulated by sphingosine kinase-1. Blood 2008;111:3489-3497.
71. Foss FW, Jr., Snyder AH, Davis MD, Rouse M, Okusa MD, Lynch KR, Macdonald TL: Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem 2007;15:663-677.
72. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K, Hla T: Phosphorylation and action of the immunomodulator fty720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003;278:47281-47290.
73. Skoura A, Hla T: Regulation of vascular physiology and pathology by the s1p2 receptor subtype. Cardiovasc Res 2009;82:221-228.
74. Kimura T, Tomura H, Mogi C, Kuwabara A, Damirin A, Ishizuka T, Sekiguchi A, Ishiwara M, Im DS, Sato K, Murakami M, Okajima F: Role of scavenger receptor class b type i and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endo-thelial cells. J Biol Chem 2006;281:37457-37467.
75. Krump-Konvalinkova V, Yasuda S, Rubic T, Makarova N, Mages J, Erl W, Vosseler C, Kirkpatrick CJ, Tigyi G, Siess W: Stable knock-down of the sphingosine 1-phosphate receptor s1p1 influences multiple functions of human endothelial cells. Arterioscler Thromb Vasc Biol 2005;25:546-552.
76. Bolick DT, Srinivasan S, Kim KW, Hatley ME, Clemens JJ, Whetzel A, Ferger N, Macdonald TL, Davis MD, Tsao PS, Lynch KR, Hedrick CC: Sphingosine-1- phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol 2005;25:976-981.
77. Whetzel AM, Bolick DT, Srinivasan S, Macdonald TL, Morris MA, Ley K, Hedrick CC: Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic nod mice through activation of the s1p1 receptor. Circ Res 2006;99:731-739.
78. Rizza C, Leitinger N, Yue J, Fischer DJ, Wang DA, Shih PT, Lee H, Tigyi G, Berliner JA: Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab Invest 1999;79:1227-1235.
79. Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, Khew-Goodall Y, Bert AG, Barter PJ, Vadas MA: Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA 1998;95:14196-14201.
80. Shimamura K, Takashiro Y, Akiyama N, Hirabayashi T, Murayama T: Expression of adhesion molecules by sphingosine 1-phosphate and histamine in endothelial cells. Eur J Pharmacol 2004;486:141-150.
81. Limaye V, Xia P, Hahn C, Smith M, Vadas MA, Pitson SM, Gamble JR: Chronic increases in sphingosine kinase-1 activity induce a pro-inflammatory, pro-angiogenic phenotype in endothelial cells. Cell Mol Biol Lett 2009;14:424-441.
82. Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, Chalfant CE, Obeid LM, Hannun YA: The sphingosine kinase 1/sphingosine-1- phosphate pathway mediates cox-2 induction and pge2 production in response to tnf-alpha. Faseb J 2003;17:1411-1421.
83. Miura Y, Yatomi Y, Ohmori T, Osada M, Ozaki Y: Independence of tumor necrosis factor-alpha-induced adhesion molecule expression from sphingosine 1-phosphate signaling in vascular endothelial cells. J Thromb Haemost 2004;2:1019-1021.
84. Kimura T, Tomura H, Mogi C, Kuwabara A, Ishiwara M, Shibasawa K, Sato K, Ohwada S, Im DS, Kurose H, Ishizuka T, Murakami M, Okajima F: Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells. Cell Signal 2006;18:841-850.
85. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, Mersmann J, Larmann J, Hermann S, Stypmann J, Schober O, Hildebrand R, Schulz R, Heusch G, Haude M, von Wnuck Lipinski K, Herzog C, Schmitz M, Erbel R, Chun J, Levkau B: High-density lipoproteins and their constituent, sphingosine-1- phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the s1p3 lysophospholipid receptor. Circulation 2006;114:1403-1409.
86. Tauseef M, Kini V, Knezevic N, Brannan M, Ramchandaran R, Fyrst H, Saba J, Vogel SM, Malik AB, Mehta D: Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res 2008;103:1164-1172.
87. Ledgerwood LG, Lal G, Zhang N, Garin A, Esses SJ, Ginhoux F, Merad M, Peche H, Lira SA, Ding Y, Yang Y, He X, Schuchman EH, Allende ML, Ochando JC, Bromberg JS: The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue t lymphocytes into afferent lymphatics. Nat Immunol 2008;9:42-53.
88. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S: Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006;1758:2016-2026.
89. Florey O, Haskard DO: Sphingosine 1-phosphate enhances fc gamma receptor-mediated neutrophil activation and recruitment under flow conditions. J Immunol 2009;183:2330-2336.
90. Milara J, Mata M, Mauricio MD, Donet E, Morcillo EJ, Cortijo J: Sphingosine-1-phosphate increases human alveolar epithelial il-8 secretion, proliferation and neutrophil chemotaxis. Eur J Pharmacol 2009;609:132-139.
91. Ishii M, Egen JG, Klauschen F, Meier-Schellersheim M, Saeki Y, Vacher J, Proia RL, Germain RN: Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009;458:524-528.
92. McVerry BJ, Garcia JG: In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: Mechanistic insights. Cell Signal 2005;17:131-139.
93. Feistritzer C, Riewald M: Endothelial barrier protection by activated protein c through par1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005;105:3178-3184.
94. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG: Activated protein c mediates novel lung endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005;280:17286-17293.
95. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW: Oral fingolimod (fty720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140.
96. Kaudel CP, Frink M, van Griensven M, Schmiddem U, Probst C, Bergmann S, Krettek C, Klempnauer J, Winkler M: Fty720 application following isolated warm liver ischemia improves long-term survival and organ protection in a mouse model. Transplant Proc 2007;39:493-498.
97. Frink M, Kaudel CP, Hildebrand F, Pape HC, Klempnauer J, Winkler M, Krettek C, van Griensven M: Fty720 improves survival after transient ischemia and reperfusion of the hind limbs. J Trauma 2007;63:263-267.
98. Tolle M, Levkau B, Keul P, Brinkmann V, Giebing G, Schonfelder G, Schafers M, von Wnuck Lipinski K, Jankowski J, Jankowski V, Chun J, Zidek W, Van der Giet M: Immunomodulator fty720 induces enos-dependent arterial vasodila-tation via the lysophospholipid receptor s1p3. Circ Res 2005;96:913-920.
99. Keul P, Tolle M, Lucke S, von Wnuck Lipinski K, Heusch G, Schuchardt M, van der Giet M, Levkau B: The sphingosine-1-phosphate analogue fty720 reduces atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:607-613.
100. Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EA: Fty720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007;115:501-508.
101. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG: Lymphocyte sequestration through s1p lyase inhibition and disruption of s1p gradients. Science 2005;309:1735-1739.
102. Olivera A, Mizugishi K, Tikhonova A, Ciaccia L, Odom S, Proia RL, Rivera J: The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity 2007;26:287-297.